GeoVax Labs, Inc. · NASDAQ:GOVX
GeoVax Labs — Bio CEO Investor Conference 2022
24 slides from GeoVax Labs's conference presentation, Feb 14, 2022
Slide 1: GeoVax, Inc.
GeoVax, Inc. February 14-17, 2022 NASDAQ: GOVX
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstanc
Slide 3: About GeoVax Labs, Inc.
About GeoVax Labs, Inc. GeoVax Labs, Inc. is a clinical-stage biotechnology company developing immunotherapies and vaccines against a wide range of infectious diseases and cancers using three novel, proprietary platforms: GV-MVA-VLP, sMVA and GDEPT The development pipeline includes vaccines and immu
Slide 4: Consolidated Balance Sheet Information
GeoVax Labs, Inc. Consolidated Balance Sheet Information (amounts in thousands, except share information) Sep 30, Dec 31, 2021 2020 Assets Cash and cash equivalents $ 18,107 $ 9,884 Other current assets 53 351 Total current assets 18,160 10,235 Property and other assets, net 180 159 Total assets $ 1
Slide 5: GeoVax Announces $10 Million Private Placement
GeoVax Announces $10 Million Private Placement ATLANTA, GA, January 14, 2022 — GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single instit
Slide 6: Pipeline Focused on Near-term Value Drivers
Pipeline Focused on Near-term Status Funding Value Drivers Coronavirus COVID-19 (Immunocompromised patients) GEO-CM04S1 Phase 2 Internal COVID-19 (Booster to mRNA) GEO-CM04S1 Phase 2 Internal Pan Coronavirus GEO-CM02 IND-Enabling Internal & Non-Dilutive Immuno-Oncology Solid Tumors (Head & Neck)* Ge
Slide 7: Infectious Disease Portfolio
Infectious Disease Portfolio 7
Slide 8: GeoVax Infectious Diseases Portfolio Jan 2021 vs. Jan 2022
GeoVax Infectious Diseases Portfolio Jan 2021 vs. Jan 2022 SARS CoV-2 Universal “Pan” Coronavirus SARS CoV-2 Universal “Pan” Coronavirus 1. Lead candidate identified - GEO-CM02 2. Preclinical testing advanced, single dose protection from variants 1. MVA-VLP based 3. Expanded research relationships u
Slide 9: Phase 2 Trial – Immunocompromised Patients
9 Covid-19 Vaccine (GEO-CM04S1) Phase 2 Trial – Immunocompromised Patients ▪ Diminished antibody responses compared to healthy vaccinated individuals have been shown in immunocompromised patients provided mRNA COVID-19 vaccines ▪ A COVID-19 vaccine which favors broader induction of cellular immune r
Slide 10: Phase 2 Trial – Booster vaccination to mRNA vaccines
0 Covid-19 Vaccine (GEO-CM04S1) Phase 2 Trial – Booster vaccination to mRNA vaccines ▪ Governments have started recommending 3rd doses of currently authorized COVID-19 vaccines ▪ In the US high risk subjects are eligible for a booster if they received Pfizer/Moderna vaccines. All individuals who hav
Slide 11: GEO-CM02 Universal Coronavirus Vaccine Results to Date
GEO-CM02 Universal Coronavirus Vaccine Results to Date • The use of MVA as a vector supports the design and production of “next- gen” vaccines encoding multiple viral proteins • S protein as the antibody target • M and E as T-cell targets • The combination of S, M and E protein expression supports V
Slide 12: GEO-CM02 & GEO-CM04S1: Synergies
GEO-CM02 & GEO-CM04S1: Synergies • The use of MVA as a vaccine vector is the core technology of GeoVax • Experimental products for use against a diverse set of infectious diseases in different stages of preclinical and clinical development • Funding partnerships with multiple US government agencies
Slide 13: Immuno-oncology Portfolio
Immuno-oncology Portfolio 13
Slide 14: GeoVax Immuno-Oncology Portfolio Jan 2021 vs. Jan 2022
GeoVax Immuno-Oncology Portfolio Jan 2021 vs. Jan 2022 MUC1 Solid tumors MUC1 Solid tumors 1. Clinical candidate selected 1. MVA-VLP based, experimental 2. GMP manufacturing initiated 2. Preclinical 3. Research and clinical testing relationships under final negotiation 3. Internal funding 4. Assembl
Slide 15: Chemotherapy and Radiation Treatments Frequently Fail
Chemotherapy and Radiation Treatments Frequently Fail ▪ These modalities fail to treat the large numbers of silent, quiescent cells in a tumor mass. ▪ The GDEPT (Gene-Directed Enzyme Prodrug Therapy) technology is specifically designed to destroy these cells. 15
Slide 16: Mechanism of Action e.g., Gedeptin
Mechanism of Action e.g., Gedeptin® F-araAMP (Fludara, Fludarabine phosphate) Gedeptin® (Ad/PNP) Plasma enzymes F-araA (Fludarabine) E. coli PNP in tumor cells Fluoroadenine Unprecedented level of cell killing activity Novel tumor killing mechanism Destroys refractory solid tumors 16
Slide 17: Approved Phase II Clinical Protocol
Approved Phase II Clinical Protocol ▪ Utilizes dose and schedule found safe and effective in Phase I/IIa trial (as a single cycle*) ▪ Up to 5 cycles will be administered ▪ The entire tumor burden will be treated * Two days of Gedeptin followed by 3 days of fludarabine 17
Slide 18: Potential Path to Regulatory Filing for FDA Approval
Potential Path to Regulatory Filing for FDA Approval ▪ Expanded enrollment completed: YE 2022 ▪ Completion of patient evaluations: YE 2023 ▪ BLA filing: H1 2024 18
Slide 19: Gedeptin Improves efficacy of check point blockade inhibitors
Gedeptin® Improves efficacy of check point blockade inhibitors Recent studies indicate that Gedeptin® treatment is additive or synergistic with checkpoint blockade type agents. Gedeptin® therapy robustly sensitizes tumors that do not express E. coli PNP to checkpoint blockade inhibitors, presumably
Slide 20: GeoVax Novel Concept to Cancer Immunotherapy
GeoVax Novel Concept to Cancer Immunotherapy Triple-threat Approach: 1 Stimulate tumor specific 2 Augment immune responses 3 Immune inhibition is blocked with checkpoint responses utilizing MVA- using homologous peptide VLP technology vaccine inhibitors STIMULATE: MVA-VLP with TAA to provoke immune
Slide 21: GeoVax MVA-VLP-MUC1 – Promising Results
GeoVax MVA-VLP-MUC1 – Promising Results Therapeutic Experiment Results Prevention “Recurrence” Experiment Results MVA-VLP-MUC1 + Peptide 1.0 No Treatment Tumor Progression Tumor Growth (cm) 500 400 Tumor Weight (mg) Untreated 0.5 300 Anti-mPD-1 alone (MVA+ MTI) + Anti-mPD-1 200 MTI+ Anti-mPD-1 (4 do
Slide 22: Strong IP for GeoVax Technology
Strong IP for GeoVax Technology Our patent portfolio covers >70 granted or pending patent • COVID-19 vaccines • Immuno-oncology • Hemorrhagic fever (Ebola, Marburg, Sudan, Lassa) applications spread over • Zika, Malaria vaccine 20 patent families • HIV • HPV-associated cancer • Hepatitis B vaccine 2
Slide 23: Pipeline Focused on Near-term Value Drivers
Pipeline Focused on Near-term Status Funding Value Drivers Coronavirus COVID-19 (Immunocompromised patients) GEO-CM04S1 Phase 2 Internal COVID-19 (Booster to mRNA) GEO-CM04S1 Phase 2 Internal Pan Coronavirus GEO-CM02 IND-Enabling Internal & Non-Dilutive Immuno-Oncology Solid Tumors (Head & Neck)* Ge
Slide 24: Thank You
Thank You Creating Vaccines to Serve Humanity For More Information GeoVax Labs, Inc. investor@geovax.com 678-384-7220 1900 Lake Park Drive, Suite 380 Atlanta, GA 30080 Tel: (678) 384-7220 Fax: (678) 384-7281 www. geovax.com NASDAQ: GOVX